COMMUNIQUÉS West-GlobeNewswire

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
23/01/2025
- REGAL Successfully Passes Event-Driven (60 Deaths) Interim Analysis for Efficacy, Futility, and Safety: The Independent Data Monitoring Committee (IDMC) Recommended Continuation of the Clinical Trial Without [...]
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies
23/01/2025
CORAL GABLES, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most Successful Mid-Cap [...]
AMN Healthcare to Hold Fourth Quarter and Full Year 2024 Earnings Conference Call on Thursday, February 20, 2025
23/01/2025
DALLAS, Jan. 23, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), has scheduled a conference call to discuss its fourth quarter and full year 2024 financial results and first quarter 2025 outlook on [...]
ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer
23/01/2025
Oral presentation at 2025 ASCO Gastrointestinal Cancers Symposium today highlights e vorpacept as the first CD47 blocker to show substantial tumor response and a well-tolerated safety profile in a prospective randomized [...]
ORYZON announces first patient dosed in an Investigator-initiated Phase I study of iadademstat in myelodysplastic syndrome
23/01/2025
Exploring the combination with azacitidine Study led by Medical College of Wisconsin MADRID and CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage [...]
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split
23/01/2025
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a multi-asset, clinical stage, disease-agnostic life science company [...]
Spur Therapeutics Announces Platform and Poster Presentations Highlighting New Clinical Data for FLT201 in Gaucher Disease at Upcoming WORLDSymposium
23/01/2025
LONDON, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced that it will share updated clinical data from its Phase 1/2 GALILEO-1 trial of FLT201, its adeno-associated virus (AAV) gene therapy candidate [...]
MBX Biosciences to Participate in Upcoming February Investor Conferences
23/01/2025
CARMEL, Ind., Jan. 23, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the [...]
Lisata Therapeutics and WARPNINE Announce Encouraging Preliminary Results from the Phase 1b/2a iLSTA Trial Evaluating Certepetide in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma
23/01/2025
Data corroborate previously reported preclinical data demonstrating certepetide’s ability to enhance the effectiveness of immunotherapy Preliminary results to be presented at the 2025 ASCO Gastrointestinal Cancers [...]
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
23/01/2025
Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE [...]
InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference
23/01/2025
JENA, Germany, Jan. 23, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will [...]
BioPorto announces the publication of urinary NGAL reference ranges in healthy adult and pediatric individuals
23/01/2025
News Release January 23, 2025 BioPorto announces the publication of urinary NGAL reference ranges in healthy adult and pediatric individuals COPENHAGEN, DENMARK, January 23, 2025 (GLOBE NEWSWIRE) – BioPorto, an in vitro [...]
Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition
23/01/2025
Private placement of $6.5 million with a global investor and entrepreneur, Mr. Alejandro Weinstein, who will join Pluri’s Board of Directors Pluri to purchase approximately 71% of Kokomodo Ltd.’s shares, a leading [...]
STERIS to Host a Conference Call for Fiscal 2025 Third Quarter Financial Results on February 6, 2025
22/01/2025
DUBLIN, IRELAND , Jan. 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2025 third quarter financial results at 9: [...]
Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab
22/01/2025
NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
Inotiv, Inc. to Report Fiscal 2025 First Quarter Financial Results and Host Conference Call on Wednesday, February 5, 2025
22/01/2025
WEST LAFAYETTE, Ind., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and [...]
Bionano Announces Effective Date of Reverse Stock Split
22/01/2025
SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO)(the “Company”) today announced that it will effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for [...]
Avid Reminds Stockholders to Vote Today FOR the Transaction with GHO and Ampersand
22/01/2025
Mails Letter to Stockholders Highlighting the Significant, Immediate and Certain Cash Value the Transaction Delivers to Stockholders TUSTIN, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO [...]
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
22/01/2025
SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical [...]

Pages